Semaglutide: Clinical Trial Analysis and Evidence Synthesis

Semaglutide has accumulated one of the most robust evidence portfolios in obesity pharmacotherapy. From the SUSTAIN glycaemic trials through the transformative STEP weight-management programme and into the landmark SELECT cardiovascular outcomes trial, no GLP-1 agonist has been subjected to such breadth of prospective investigation.

Pharmacological Profile

Semaglutide is a human GLP-1 analogue with 94% sequence homology to native GLP-1 (7–37). Two structural modifications drive its pharmacokinetics: a C-18 fatty diacid chain confers strong, reversible albumin binding, while a substitution at position 8 (alanine to α-aminoisobutyric acid) renders the molecule resistant to DPP-4 proteolysis. The combined effect is a plasma half-life of approximately 165–184 hours — enabling once-weekly subcutaneous administration and, unusually for a peptide, once-daily oral administration with the SNAC absorption enhancer.

Three commercial formulations are currently FDA-approved: Ozempic (semaglutide 0.5–2 mg SC weekly, type 2 diabetes), Rybelsus (semaglutide 7–14 mg oral daily, type 2 diabetes), and Wegovy (semaglutide 2.4 mg SC weekly, chronic weight management). The obesity indication represented the first approval of a new anti-obesity medication since lorcaserin in 2012, and semaglutide's effect size substantially exceeded that of any predecessor.

The STEP Programme: Defining Efficacy in Obesity

The Semaglutide Treatment Effect in People with obesity (STEP) programme enrolled over 4,500 participants across four pivotal trials. STEP 1 — 1,961 adults with BMI ≥30 kg/m² or ≥27 with at least one weight-related comorbidity — remains the foundational efficacy trial for Wegovy. At 68 weeks, semaglutide 2.4 mg produced a mean weight reduction of 14.9% from baseline versus 2.4% with placebo (treatment difference: −12.4 percentage points; 95% CI −13.4 to −11.5; p<0.001).

Response distribution data are arguably more clinically meaningful than means. Among semaglutide-treated participants: 69.1% achieved ≥10% weight loss, 50.5% achieved ≥15%, and 32.0% achieved ≥20% — compared with 12.0%, 4.9%, and 1.7% on placebo, respectively. The one-in-three probability of achieving what was historically considered surgical-level weight loss is a striking benchmark.

STEP 2 enrolled adults with both obesity and type 2 diabetes — a population in whom weight loss is generally more attenuated with pharmacotherapy. Mean weight reduction was 9.6% with semaglutide 2.4 mg versus 3.4% with placebo. STEP 3 added intensive behavioural intervention, producing 16.0% weight reduction — suggesting meaningful additive effects with lifestyle support. STEP 4 was a withdrawal trial: participants who had lost weight on semaglutide during a 20-week run-in were randomised to continue or switch to placebo. The semaglutide group maintained their weight loss; the placebo group regained approximately two-thirds of lost weight by week 68 — reinforcing the growing consensus that obesity is a chronic disease requiring long-term pharmacological management.

SELECT: Cardiovascular Risk Reduction Without Diabetes

Published in the New England Journal of Medicine in November 2023, the SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial enrolled 17,604 adults with pre-existing cardiovascular disease (history of MI, stroke, or peripheral arterial disease), a BMI ≥27 kg/m², but without diabetes — the first large CVOT in a primary obesity (non-diabetic) population.

Over a median follow-up of 39.8 months, semaglutide 2.4 mg reduced the risk of the primary MACE endpoint — non-fatal MI, non-fatal stroke, or cardiovascular death — by 20% versus placebo (HR 0.80; 95% CI 0.72–0.90; p<0.001). This hazard ratio is comparable to those seen with statins in secondary prevention. The mechanism underlying the cardiovascular benefit is not fully resolved; weight loss, direct vascular effects, anti-inflammatory activity, and improved haemodynamics are all plausible contributors and likely act in combination.

Safety Profile: What the Trial Data Show

Gastrointestinal adverse events are the dominant tolerability concern: nausea was reported in 44.2% of semaglutide participants versus 16.1% on placebo in STEP 1. Vomiting (24.8% vs 6.8%) and diarrhoea (29.7% vs 15.9%) were also significantly more frequent. Discontinuation due to GI events occurred in 4.5% of the semaglutide group — a non-trivial rate that emphasises the importance of gradual dose escalation over 16 weeks. Nausea onset is highest during titration and typically attenuates thereafter.

Serious adverse events of specific concern include acute pancreatitis (reported in 0.3% of semaglutide participants across STEP trials), gallbladder disease — particularly cholelithiasis (2.6% vs 1.2% in STEP 1, likely mediated by rapid weight loss rather than GLP-1 mechanism directly), and a theoretical risk of medullary thyroid carcinoma based on rodent pharmacology, for which no human signal has emerged in post-marketing surveillance.